The Uniqueness of Albumin as a Carrier in Nano Drug Delivery

Yash Gupta; Vishal Rai; Anushka Singh; Soban Khan; Nisha Bano; Reena Yadav

doi:10.55544/jrasb.3.1.2

Authors

Yash Gupta Department of Pharmacy, Dr. M.C. Saxena College of Pharmacy, Uttar Pradesh, INDIA.
Vishal Rai Department of Pharmacy, Dr. M.C. Saxena College of Pharmacy, Uttar Pradesh, INDIA.
Anushka Singh Department of Pharmacy, Dr. M.C. Saxena College of Pharmacy, Uttar Pradesh, INDIA.
Soban Khan Department of Pharmacy, Dr. M.C. Saxena College of Pharmacy, Uttar Pradesh, INDIA.
Nisha Bano Department of Pharmacy, Dr. M.C. Saxena College of Pharmacy, Uttar Pradesh, INDIA.
Reena Yadav Department of Pharmacy, Dr. M.C. Saxena College of Pharmacy, Uttar Pradesh, INDIA.

DOI:

https://doi.org/10.55544/jrasb.3.1.2

Keywords:

Albumin, Nanodelivery, Globular protein, Colloid osmotic pressure

Abstract

The quest for precision medicine hinges on targeted drug delivery, minimizing off-target effects while maximizing therapeutic impact. Among nanocarriers, albumin – the most abundant protein in human blood – emerges as a uniquely biocompatible stealth bomber. Its inherent advantages, including exceptional biodegradability, prolonged circulation, and natural affinity for diseased tissues, perfectly align with the goals of personalized medicine. Albumin readily solubilizes poorly soluble drugs, enhancing bioavailability and broadening the therapeutic arsenal. Its versatile surface allows for targeted modifications, enabling dual diagnosis and treatment (theranostics) tailored to individual needs. While challenges remain in optimizing drug loading and targeting specificity, albumin-based nanocarriers hold immense promise for revolutionizing personalized healthcare, delivering potent therapeutics with pinpoint accuracy.

The burgeoning field of nanodrug delivery seeks to redefine therapeutic landscapes by engineering nanoscale carriers that meticulously deliver potent drugs to their designated targets, minimizing systemic exposure and maximizing therapeutic efficacy. This pursuit aligns perfectly with the burgeoning field of precision medicine, where personalized treatments demand exquisite control over drug delivery. Within this intricate choreography, albumin, the abundant and versatile protein resident in human plasma, emerges as a maestro, orchestrating a symphony of advantages that make it a prime candidate for nanocarrier construction.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Elsabahy, M., & Kratz, F. (2010). Albumin-based drug delivery: rationale, design and applications. Journal of Controlled Release, 145(3), 301-316.

Wang, Y., Xu, H., & Zhou, C. (2022). Human Serum Albumin Based Nanodrug Delivery Systems: Recent Advances and Future Perspective. Molecules, 15(16), 3084.

Nabata, Y., & Yokoyama, T. (2016). Nanoparticles for targeted cancer therapy: design and applications. Journal of Drug Targeting, 24(1-2), 127-137.

Peters, T., Jr. (2017). Albumin. (4th ed.). Academic Press.

Sugiyama, S., Ikenaga, S., & Okuda, K. (2017). Human serum albumin: structural basis of its multifunctional properties. Journal of Drug Targeting, 25(8), 579-592. https://www.ncbi.nlm.nih.gov/books/NBK55072/

Sugiyama, S., Ikenaga, S., & Okuda, K. (2017). Human serum albumin: structural basis of its multifunctional properties. Journal of Drug Targeting, 25(8), 579-592. https://www.ncbi.nlm.nih.gov/books/NBK55072/](https://www.ncbi.nlm.nih.gov/books/NBK55072/):[https://www.ncbi.nlm.nih.gov/books/NBK55072/](https://www.ncbi.nlm.nih.gov/books/NBK55072/

Elsabahy, M., & Kratz, F. (2010). Albumin-based drug delivery: rationale, design and applications. Journal of Controlled Release, 145(3), 301-316.

Wang, Y., Xu, H., & Zhou, C. (2022). Human Serum Albumin Based Nanodrug Delivery Systems: Recent Advances and Future Perspective. Molecules, 15(16), 3084.

Nabata, Y., & Yokoyama, T. (2016). Nanoparticles for targeted cancer therapy: design and applications. Journal of Drug Targeting, 24(1-2), 127-137.

Sugiyama, S., Ikenaga, S., & Okuda, K. (2017). Human serum albumin: structural basis of its multifunctional properties. Journal of Drug Targeting, 25(8), 579-592.

Cheng, Y., He, W., Li, J., Sun, J., Gao, H., Cheng, R., ... & Yuan, W. (2020). Multifunctional albumin nanosystems for targeted anti-tumor drug delivery and therapy. Biomaterials, 119, 55-67.

Bhattacharya, K., Mukherjee, S., & Chandra, P. (2012). Albumin nanoparticles for targeted drug delivery: progress and challenges. Journal of Nanoscience and Nanotechnology, 12(12), 4900-4913

Yang, H., He, J., He, X., Wang, M., Huang, Y., Sun, X., & Tang, F. (2013). Albumin-conjugated paclitaxel nanoparticles prepared by solvent evaporation method: physicochemical properties and in vitro/vivo evaluation. International Journal of Pharmaceutics, 441(1-2), 704-714.

Zhang, Z., Sun, X., Shen, Y., Zhang, W., Zeng, Y., Zhu, X., ... & Li, X. (2011). Albumin-conjugated nanoparticles bearing paclitaxel for targeting drug delivery against glioma. Biomaterials, 32(30), 7705-7714.

Chen, R., Zhang, X., He, J., Chen, M., Wu, X., Chen, G., ... & Yin, W. (2022). Development of HSA-targeted paclitaxel prodrug nanoparticles for synergistic inhibition of tumor angiogenesis and cancer growth. Acta biomaterialia, 149, 155-166.**

Li, M., Li, W., Song, W., Li, B., Wang, J., Sun, J., ... & Chen, X. (2021). Construction of Multifunctional Human Serum Albumin Nanoparticles for Co-delivery of Docetaxel and Bcl-2 siRNA for Enhanced Synergistic Chemo-Gene Therapy. Molecular Pharmaceutics, 18(7), 2205-2216.